Want to track AVR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy
Anteris Technologies Global (NASDAQ: AVR) CEO and founder Wayne Paterson discussed the company's DurAVR transcatheter aortic valve replacement (TAVR) program, recent clinical visibility, and the company's approach to market development during a conversation that touched on product design, tissue science, reimbursement, and longer-term interest in heart failure care pathways. Clinical interest and a "total disease management"
Defenseworld | 7 months ago
2026 © Marketlog. All Rights Reserved.
